B+
Bull case
25%
Probability
Target price
$72.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
XENE
XenonDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Xenon has materially de-risked azetukalner in epilepsy with a positive Phase 3 X-TOLE2 readout, stated an NDA timing target for Q3 2026, and bolstered liquidity through both ATM activity and the March 2026 upsized offering; that combination supports continued commercial-readiness work and broader pipeline execution [#PR-2026-03-09] [#PR-2026-03-12] [#10-K-2026-02-26].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +6.7.
What can break
Clinical read-through risk if later epilepsy or neuropsychiatry studies fail to match the strength of X-TOLE2.
Momentum
26
Value
41
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $58.00 · Bull $72.00 · Bear $42.00Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $81.25
Why
Momentum26 · Δ7d +3.1
Value41 · Δ7d 0.0
Sentiment60 · Δ7d +6.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +6.7.
Contradictions & invalidation
- • Clinical read-through risk if later epilepsy or neuropsychiatry studies fail to match the strength of X-TOLE2.
- • Commercial-readiness and launch-execution risk as Xenon moves toward a potential first product.
- • The stock remains a concentrated single-asset story despite multiple studies, near-term catalyst density is now thinner after the March data release, operating burn is elevated, and dilution has risen after substantial equity issuance; even the April 2026 inducement-plan increase is a reminder that share count pressure remains part of the story [#PR-2026-03-12] [#8-K-2026-04-13].
Catalyst clock
2026-04-19
AAN late-breaking X-TOLE2 presentation on April 19, 2026
Lead driver: Sentiment · See AI snapshot
Momentum
26
9% active weight
Current posture
7d trendImproving
Δ7d
+3.1
Δ21d
-29.7
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
60
62% active weight
Current posture
7d trendImproving
Δ7d
+6.7
Δ21d
+9.2
Why this grade
Composite grade D. Momentum 25.7 / Value 41.2 / Sentiment 60.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$58.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$42.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$6.04B
Beta
0.96
Shares Out
96.84M
P/E (TTM) · Derived
-14.3
P/S (TTM)
430.58
P/FCF (TTM) · Derived
-16.07
Rev YoY
-100.0%
EPS YoY
+3.6%
Gross Margin
+66.1%
Op Margin
-4543.7%
Net Debt
-$540.94M
Current Ratio
21.02
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data